New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Click here to view this article.
Related Videos
Related Content
